Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer. The TPST news feed on Stock Titan aggregates company announcements, financial updates, and regulatory milestones that shape the outlook for this oncology-focused biotech.
Investors following TPST news can expect frequent updates on the progress of Tempest’s key programs, including amezalpat (TPST-1120), a selective PPAR⍺ antagonist in development for hepatocellular carcinoma, and TPST-1495, a dual EP2/4 prostaglandin receptor antagonist being advanced for familial adenomatous polyposis. News items often highlight clinical data presentations, regulatory designations from agencies such as the FDA, EMA and China’s NMPA, and clearances or agreements for pivotal or registration-directed trials.
The company also regularly reports quarterly financial results and business updates, detailing research and development spending, cash position, and its ongoing evaluation of strategic alternatives. Capital markets activity, such as registered direct offerings of common stock, private placements of warrants, and shelf registration usage, is disclosed through press releases and corresponding SEC filings and is reflected in the TPST news stream.
In addition, Tempest issues news on strategic transactions, including its agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates, which is intended to expand and diversify its clinical-stage pipeline. For market participants tracking TPST, this news page provides a centralized view of clinical, regulatory, financial, and transactional developments. Users interested in Tempest’s evolving oncology pipeline and corporate strategy can review past announcements and monitor new releases as they are published.
Tempest (Nasdaq: TPST) will present clinical updates for its dual-targeting CAR-T candidate TPST-2003 at ISCT 2026 in Dublin, May 6-9. Data include REDEEM-1 Phase 1/2a interim results showing a 100% complete response rate among six then-evaluable patients per IMWG criteria and a reported favorable safety profile. Presentations include an oral talk (May 6) and poster reception (May 7).
Tempest (Nasdaq: TPST) delivered the TPST-2003 lentiviral vector to Cincinnati Children’s AGCTC, enabling manufacturing activities needed for pivotal development of the dual-targeting CD19/BCMA CAR-T for relapsed/refractory multiple myeloma.
Tempest reported a 100% overall response rate (25/25) across evaluable patients and 100% complete responses in six REDEEM-1 efficacy-evaluable patients; median PFS was 23.1 months in the investigator-initiated trial. Tech transfer is on track to support initiation of a potentially registrational study in Q4 2026.
Tempest (Nasdaq: TPST) appointed Andrew Fang, Ph.D., as Head of Business Development on April 14, 2026, to lead global partnerships, cross-border licensing and China outreach. The hire targets partnering for the Phase 3-ready small molecule amezalpat program and strategic collaborations across Tempest’s CAR-T portfolio.
The company noted prior regulatory alignment with FDA and EMA and clearance to pursue a pivotal trial of amezalpat in China, positioning the program for potential global development and regional licensing opportunities.
Tempest (Nasdaq: TPST) reported year-end 2025 results and a corporate update on March 30, 2026. Key developments include the strategic all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience, positive interim REDEEM-1 data for TPST-2003 (100% CR in six evaluable patients), regulatory designations for amezalpat, and multiple equity financings.
Financially, cash fell to $7.7M at year-end 2025 from $30.3M, net loss was $26.3M, R&D spend was $12.6M, and Tempest noted partner-funded development strategies moving forward.
Tempest Therapeutics (Nasdaq: TPST) announced a private placement expected to close on or about March 23, 2026 to raise up to $6 million in aggregate proceeds: approximately $2 million upfront and up to $4 million if warrants are fully exercised.
The offering covers 925,927 shares (or pre-funded warrants) and accompanying series A and short-term series B warrants priced at $2.16 per share; warrants require stockholder approval and have defined expiry periods. Proceeds are for working capital and general corporate purposes.
Tempest (Nasdaq: TPST) selected Cincinnati Children’s Applied Gene and Cell Therapy Center (AGCTC) to conduct technology transfer, development and IND‑enabling manufacturing for TPST-2003, a dual‑targeting CD19/BCMA CAR‑T for relapsed/refractory multiple myeloma.
As of a January 31, 2026 cutoff, 36 patients received TPST-2003; all six efficacy‑evaluable REDEEM-1 patients achieved complete response and overall response rate was 100% (25/25) among evaluable patients. Most activities are planned complete by Q3 2026 to support a potential IND filing in Q4 2026.
Tempest (NASDAQ: TPST) reported interim REDEEM-1 results for TPST-2003, a CD19/BCMA dual-targeting CAR-T. Across two studies 36 patients treated; among 25 evaluable with measurable disease ORR was 100% (25/25), and all six REDEEM-1 efficacy-evaluable patients achieved CR. Safety showed no Grade >=3 CRS or ICANS. Tempest plans a U.S. IND submission and, subject to clearance, to initiate a U.S. registrational study in 2026.
Tempest Therapeutics (Nasdaq: TPST) outlined a capital-efficient plan to advance newly acquired dual-targeting CAR-T assets, prioritizing partner-funded development to preserve internal capital. Key priorities include advancing TPST-2003 with near-term Phase 1 data from China, a registrational Phase 2b planned by end-2026, and interim data expected in 2027.
The pipeline expansion includes TPST-4003, an in vivo CD19/BCMA CAR-T program aimed at preclinical development and partner-funded investigator trials, plus continued development of amezalpat (Phase 3-ready HCC) and a NCI-funded Phase 2 for TPST-1495 with enrollment expected in Q1 2026.
Tempest (Nasdaq: TPST) closed an all-stock acquisition of dual-targeting CAR-T programs and secured strategic partner funding from Factor Bioscience, adding clinical-stage assets including TPST-2003. The deal extends operational runway to mid-2027, supports multiple near-term milestones, and installs Matt Angel, Ph.D., as President and CEO.
Key program highlights: TPST-2003 has completed a Phase 1 rrMM study with China BLA planned for 2027; TPST-2003 is enrolling POEMS patients with data and a China BLA planned by 2028; TPST-1120 remains Phase 3 ready in first-line HCC.
Tempest Therapeutics (Nasdaq: TPST) announced a record date of January 30, 2026 for a dividend distribution of warrants to purchase common stock (one warrant per share). The distribution is expected on February 3, 2026, subject to closing conditions under an Asset Purchase Agreement and stockholder approval of Proposal 5.
The warrants expire five years after distribution at 5:00 p.m. NYC and have an initial exercise price of $18.48 per share; exercisability requires an effective registration statement covering the underlying shares.